Subsequently, agents targeting human epidermal growth factor receptor 2 (HER-2)-overexpressing breast or gastric cancer, BRAF V600E-mutation melanoma, and EGFR-, ALK-, and ROS1-mutation lung cancer enables patients with those molecular alterations to have a significantly prolonged life expectancy. The gene discussed is BRAF; the disease is melanoma.